Which Lung Cancer Mutations Have Approved Targeted Therapies?
Justin F. Gainor, M.D., shares which lung cancer mutations have approved targeted therapies in this clip from our expert panel discussion on lung cancer tumor testing. For more information and to see the full recorded discussion, visit Lung.org/tumor-testing-videos.
Generously supported by AstraZeneca, Bristol-Myers Squibb, Foundation Medicine, Pfizer, and Merck & Co., Inc.
What lung cancer mutations have approved targeted therapies?
In the United States there are four genetic changes where we have FDA-approved therapies. So these are EGFR which is found in about 10-15 percent of patients, ALK which is 3-5 percent, ROS1 which is 1-2 percent, and BRAF which is a very specific genetic change which is about 2 percent.
Page Last Updated: November 9, 2018
Sign up for the latest lung health news delivered right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.